l e t t e r s
Breast cancer is the most common cancer in women in developed countries. To identify common breast cancer susceptibility alleles, we conducted a genome-wide association study in which 582,886 SNPs were genotyped in 3,659 cases with a family history of the disease and 4,897 controls. Promising associations were evaluated in a second stage, comprising 12,576 cases and 12,223 controls. We identified five new susceptibility loci, on chromosomes 9, 10 and 11 (P = 4.6 × 10 −7 to P = 3.2 × 10 −15 ). We also identified SNPs in the 6q25.1 (rs3757318, P = 2.9 × 10 −6 ), 8q24 (rs1562430, P = 5.8 × 10 −7 ) and LSP1 (rs909116, P = 7.3 × 10 −7 ) regions that showed more significant association with risk than those reported previously. Previously identified breast cancer susceptibility loci were also found to show larger effect sizes in this study of familial breast cancer cases than in previous population-based studies, consistent with polygenic susceptibility to the disease.
Genome-wide association studies (GWAS) provide a powerful approach to identify common disease alleles. Recent GWAS have identified common variants at 12 loci that are associated with an increased risk of breast cancer, and an additional locus, CASP8 (specifically, a polymorphism resulting in a D302H substitution), has been identified through a candidate-gene association study [1] [2] [3] [4] [5] [6] [7] [8] . However, because the risks associated with these variants are modest (per-allele odds ratios (OR) <1.3), they explain only a small fraction of the estimated twofold familial relative risk of breast cancer in first-degree relatives of affected women. Moreover, the GWAS conducted to date have been relatively small, and it is likely that many susceptibility variants have been missed due to lack of power in these studies. In an attempt to identify additional breast cancer loci, we conducted a GWAS that was substantially larger than those conducted to date.
We studied 3,960 cases of breast cancer from the UK, selected for a positive family history of breast cancer. We selected cases with a positive family history because, under a polygenic model of susceptibility, this is expected to increase the effect size and hence improve study power 9 . DNA samples from these women were genotyped using an Illumina Infinium 660k array. Case genotypes were compared with those from 5,069 controls, drawn from two UK population-based studies. After quality control exclusions, we utilized data on 582,886 SNPs in 3,659 cases and 4,897 controls (Online Methods).
Genotype frequencies in cases and controls were compared using a 1-degree-of-freedom (d.f.) Cochran-Armitage trend test ( Fig. 1; for the quantile-quantile plot see Supplementary Fig. 1 ). There was modest evidence for inflation in the test statistic (λ = 1.12, which is equivalent to λ 1,000 = 1.03 for a study of 1,000 cases and 1,000 controls). Adjustment for differential population structure using the first two components based on a principal-components analysis of uncorrelated SNPs reduced the inflation to λ = 1.06 (Online Methods).
We observed evidence of association for all 12 of the susceptibility loci identified through previous GWAS, using the same SNP as that previously identified or a strongly correlated SNP (P = 0.02 to P = 3.6 × 10 −31 ; Table 1 ). Seven of these loci reached P < 10 −4 , among which five have previously been evaluated in large collaborative analyses of casecontrol studies by the Breast Cancer Association Consortium (BCAC). The BCAC analyses involved more than 20,000 cases and 20,000 controls, providing a reliable estimate of the per-allele OR 1, 5, 10 . For each of these five SNPs, the per-allele OR in the current study was higher than that estimated from the population-based studies by BCAC by a factor of 1.46-fold to 1.75-fold (P < 0.05 for difference in OR for all SNPs except rs13281615; Supplementary Table 1 ). This enrichment is broadly consistent with the selection of cases with a family history, assuming a multiplicative polygenic model (which predicts a 1.5-fold higher excess relative risk for the associated SNP for women with l e t t e r s one affected first-degree relative and a twofold higher excess relative risk for women with two affected first-degree relatives) 9 . The loci on 5p12 (rs7716600, a surrogate for rs10941679) and 1p11.2 do not conform to this pattern, having smaller ORs than those published previously (a 1.5-fold higher excess OR can be excluded here in each case, P = 0.018 and P = 0.015, respectively). These results suggest either that the initial effect sizes were overestimated (perhaps due to 'winner's curse') or that these loci have weaker than expected effects in women with a family history due to a different model of susceptibility than is applicable for the other loci. We also found limited evidence in support of the association with the CASP8 D302H polymorphism (P = 0.14; Table 1 ) 8 . Consistent with previous results, the two loci showing the largest effect sizes and most significant associations in this GWAS were on chromosome 10, in intron 2 of FGFR2 (rs2981579, P = 3.6 × 10 −31 ) and at the TOX3 locus on 16q (rs3803662, P = 3.2 × 10 −15 ).
For three loci (6q25.1, LSP1 and 8q24) we identified a SNP that showed a more significant association than the SNP originally reported associated to breast cancer susceptibility. The SNP with the lowest P value at 6q25.1 (rs3757318, P = 2.9 × 10 −6 ) lies ~200 kb upstream of ESR1 in an intron of C6orf97. In Europeans, rs3757318 is only weakly correlated with rs2046210, which has previously been identified as a susceptibility SNP 7 in a study from Shanghai (r 2 = 0.088), though these two SNPs are more strongly correlated in an East Asian population (r 2 = 0.48 in HapMap CHB). Both rs3757318 and rs6900157 (a surrogate for rs2046210 with r 2 = 0.96) remained significantly associated with breast cancer after multiple logistic regression analysis (P = 0.0003 and P = 0.002, respectively). These results suggest either the presence of a single causal variant that is more strongly correlated with rs3757318 than rs2046210 in Europeans or the presence of two causal variants. The more strongly associated SNPs that we identified in the 8q24 and LSP1 regions lie within the same linkage disequilibrium (LD) blocks as the originally identified SNP, and in each case, the original SNP was not significantly associated with risk after adjusting for the new SNP. Thus, these results may reflect the same underlying association and should assist in narrowing the search for the true causal variants. A more strongly associated variant, rs10931936, was also identified at the CASP8 locus (P = 0.0014, r 2 = 0.13).
After eliminating SNPs in previously identified susceptibility regions, we identified 28 SNPs in 13 regions of LD that were significant at P < 0.00001. After eliminating SNPs that were strongly correlated, we attempted to replicate these associations by genotyping 15 SNPs in 0.14 a Allele (frequency of the second listed allele). b Per-allele OR for the second listed allele, relative to the first. In each case the second listed allele was that which correlated with the second-listed published allele. c r 2 between the published SNP and most significant SNP in this study based on HapMap CEU. d r 2 between the published SNP and the best tagSNP in this study based on HapMap CEU. e Note that fine-mapping and functional analyses suggest that the strongest association for breast cancer is with rs2981578 25 . It is correlated with rs2981579 and rs2981582 at r 2 = 0.85. No more strongly correlated tag for rs2981578 was typed in the GWAS. f Estimated OR in Europeans. Estimated OR in Chinese was 1.36. l e t t e r s a second stage involving 11,431 cases and 11,081 controls from four studies in the UK and The Netherlands (Online Methods). We also incorporated available data from 1,145 cases and 1,142 controls from the Cancer Genetic Markers of Susceptibility (CGEMS) study. Six SNPs from five regions on chromosomes 9,10 and 11 showed clear evidence of replication in stage 2 (P = 0.0017 or better and in the same direction as stage 1) and reached significance levels over both stages combined of P = 4.6 × 10 −7 to P = 3.2 × 10 −15 ( Table 2 and Supplementary Tables 2  and 3 ). rs614367 and rs624797, which both showed strong evidence of association, were correlated, and rs624797 showed no independent association after adjustment for rs614367. The per-allele OR was higher in stage 1 than stage 2 for each SNP (P < 0.05 in each case; Supplementary Table 2 ). This may reflect either winner's curse or the enrichment of stage 1 for cases with a positive family history. There was no evidence for heterogeneity in the per-allele ORs among the stage 2 samples, with the exception of the weak evidence shown for rs10995190 (P = 0.08; Supplementary Table 2 ). There was no evidence for departure from a log-additive model for any SNP (that is, the OR for rare homozygotes did not differ significantly from the square of the OR for heterozygotes). There was weak evidence of a decrease in the per-allele OR with age for rs1011970 and of an increase in the per-allele OR with age for rs614367 (P = 0.071 and P = 0.068; Supplementary Table 4 ). rs614367 and rs624797 (but no other SNPs) showed a consistently stronger association with a positive family history in both stages (for rs614367, P = 0.006 and P = 0.00016, respectively; for rs624797, P = 0.012 and P = 0.001, respectively; Supplementary Table 4 ). For four of the SNPs (rs10995190, rs1011970, rs614367 and rs624797), the estimated per-allele ORs were higher for estrogen receptor-positive disease and showed little association in estrogen receptor-negative breast cancer, consistent with the pattern seen for the majority of breast cancer loci identified to date. For rs2380205 and rs704010, the per-allele ORs for estrogen receptor-positive and estrogen receptor-negative disease were similar, but the number of estrogen receptor-negative cases used was too small to draw firm conclusions on the effect sizes for this subset (Supplementary Table 4) .
To examine whether there was evidence for a more strongly associated variant in any of the above regions, we used imputation to estimate the genotype probabilities in the stage 1 data at known SNPs in region using the HapMap CEU data as a framework. On chromosome 11, we identified four SNPs that showed a more significant association than rs614367 (most significantly associated SNP rs6610204; P = 4.6 × 10 −14 ; Supplementary Table 5 ). In the other regions, no SNPs showed associations that were more significant than the original SNP. We also estimated the ORs associated with haplotypes of SNPs in each of the five regions (Supplementary Table 6 ). In each case, the association was present on more than one haplotype carrying the risk allele for the initially associated SNP, suggesting that the associations are unlikely to be driven by a single rare, high penetrance variant. For the chromosome 11 region, there was evidence of association with risk for two related haplotypes carrying the T allele of rs614367 with a combined frequency of 4%, suggesting that the causal variant may be somewhat rarer than the 15% minor allele frequency of rs614367.
SNP rs1011970 lies in a 180-kb block on 9p21 that includes CDKN2A and CDKN2B. These two genes encode cyclin-dependent kinase inhibitors and are frequently mutated or deleted in a wide variety of human tumors 11 . Germline mutations in CDKN2A predispose to malignant melanoma and pancreatic cancer 12 , and recent GWAS also identified rs1011970 to be associated with melanoma risk 13 ; SNPs within this same region are associated with nevus density and melanoma 14 , basal cell carcinoma 15 , glioma 16, 17 , diabetes 18 and coronary heart disease 19 . This is the first example of the same common variant predisposing to breast cancer and another cancer type rs10757278, which is correlated with rs1011970 (r 2 = 0.7), is associated with levels of expression in lymphocytes of CDKN2A, CDKN2B and a noncoding RNA in the same block, CDKN2BAS (also known as ANR1L) 20 . rs614367 on 11q13 lies in an LD block of ~166 kb that contains no annotated genes. This region is frequently amplified in human tumors, including breast cancers 21 . Plausible genes flanking this block include: proximally, MYEOV, a gene overexpressed in myeloma; distally, CCND1, encoding cyclin D1, a protein critical for cell-cycle control that is somatically altered in many tumor types; ORAOV1, a gene overexpressed in oral cancer; and three genes encoding fibroblast growth factors, FGF19, FGF4 and FGF3. FGF3 and FGF4 are l e t t e r s oncogenic growth factors that bind distinct FGFR2 isoforms, providing a possible link with the FGFR2 susceptibility locus 22 . rs10995190 on chromosome 10 lies within intron 4 of ZNF365, which encodes zinc finger protein 365. An amino acid substitution in this gene has been associated with uric acid nephrolithiasis 23 . Recent GWAS have identified another variant within this gene, rs10995271, located 159 kb downstream of rs10995190, to be associated with Crohn's disease 24 . rs2380205 lies in a 105-kb block on chromosome 10 containing the genes ANKRD16 (encoding ankyrin repeat domain 16) and FBXO18 (encoding the F-box protein, helicase 18). rs704010 on chromosome 10 lies in a 20-kb block 90 kb upstream of ZMIZ1 (encoding zinc finger MIZ-type containing 1).
Based on the estimated per-allele ORs from stage 2 of our study, the newly identified loci explain approximately 1.2% of the familial risk of breast cancer, though the overall contribution may be larger because the true causal variants may be more strongly associated with disease than the SNPs tagging them in this study. Taken together with estimates from previous studies, the 18 confirmed breast cancer susceptibility loci explain approximately 8% of the familial risk of breast cancer, whereas rarer mutations in the known high risk loci (principally BRCA1 and BRCA2) and moderate risk loci explain a further ~20%. This is by far the largest breast cancer GWAS to date and confirms that the FGFR2 and TOX3 loci (conferring per-allele ORs between 1.2 and 1.3) have the largest effect sizes from among the common susceptibility loci that are detectable with the current high-coverage genome-wide SNP sets. The residual familial risk is therefore likely to be due to a combination of a large number of common variants with smaller effects together with rarer variants not testable with current arrays. It is likely that many additional loci will be identifiable through more extensive follow-up of data from this and other GWAS. 
